For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

FLEX by Fenwick is the only service created by an AmLaw 100 firm that provides flexible and cost-effective solutions for interim in-house legal needs to high-growth companies.  MORE >

Fenwick & West handles significant cross-border legal and business issues for a wide range of technology and life sciences who operate internationally..  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Named Technology Group of the Year by Law360
  • Ranked #1 in the Americas for number of technology deals in 2015 by Mergermarket
  • Nearly 20 percent of Fenwick partners are ranked by Chambers
  • Consistently ranked among the top 10 law firms in the U.S. for diversity
  • Recognized as having top mentoring and pro bono programs by Euromoney


We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041

San Francisco Office
555 California Street
12th Floor
San Francisco, CA 94104

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101

New York Office
1211 Avenue of the Americas
32nd Floor
New York, NY 10036

Shanghai Office
Unit 908, 9/F, Kerry Parkside Office
No. 1155 Fang Dian Road
Pudong New Area, Shanghai 201204
P.R. China
+86 21 8017 1200

Tax Alert: Qualifying Therapeutic Discovery Project Credits and Grants

The enactment on March 23, 2010 of the Patient Protection and Affordable Care Act of 2010 established a 50% nonrefundable tax credit for qualified investments in qualifying therapeutic discovery projects of eligible taxpayers. The Secretary of the Treasury will, upon application by a taxpayer, provide the taxpayer with a grant of 50% of the qualified investment in lieu of the tax credit.

The credits and grants are available only with respect to investments made in a taxable year beginning in 2009 or 2010 by employers with 250 or fewer employees. The total amount of credits and grants allocated to the program may not exceed $1 billion for this two-year period.

The Tax Credit

The qualifying therapeutic discovery project credit for any taxable year is an amount equal to 50% of the qualified investment for such taxable year with respect to any qualifying therapeutic discovery project of an eligible taxpayer. A qualifying therapeutic discovery project is a project which is designed:

  • To treat or prevent diseases or conditions by conducting pre-clinical activities, clinical trials, and clinical studies or by carrying out research protocols,
  • To diagnose diseases or conditions or to determine molecular factors related to diseases or conditions by developing molecular diagnostic guide therapeutic decisions, or
  • To develop a product, process, or technology to further the delivery or administration of therapeutics.

The qualified investment for any taxable year is the aggregate amount of the costs paid or incurred in that taxable year for expenses necessary for and directly related to the conduct of a qualifying therapeutic discovery project. Only amounts certified by the Secretary of the Treasury as eligible for the credit are considered qualified investments. The qualified investment does not include certain remuneration costs, interest expenses, facility maintenance expenses, service costs or any other expenditure determined by the Secretary of Treasury as appropriate to exclude.

Furthermore, the Secretary of Treasury is to take into consideration, when making its certification determinations, only those projects that show reasonable potential to:

  • Result in new therapies to treat areas of unmet medical need or to prevent, detect or treat chronic or acute diseases and conditions,
  • To reduce long-term health care costs in the U.S., or
  • To significantly advance the goal of curing cancer within the next 30 years.

The Secretary will also take into consideration which projects have the greatest potential to create and sustain high quality, high paying jobs in the U.S. and to advance U.S. competitiveness in the fields of life, biological, and medical sciences.

The Secretary is to establish a program to consider and award the certifications for the credits on or before May 21, 2010. Each applicant for certification is to submit its application in the manner the Secretary specifies, and the Secretary is to take action to approve or deny the application within 30 days of the submission.

Companies may not claim the therapeutic discovery project credit for any investment for which bonus depreciation is allowed. In addition, with certain exceptions, expenditures included in the amount of the credit are nondeductible. Lastly, taxpayers may not include any expenses accounted for under the credit as expenses under the section 41 research credit or the section 45C orphan drug credit.

The Grant in Lieu of the Tax Credit

A company may elect to receive a grant in lieu of the preceding tax credit in the amount of 50% of the qualified investment. The company must still submit an application for certification which must contain the information specified by the Secretary of Treasury. The Secretary is then to pay the grant within 30 days of the date of the application for such certification or the date the qualified investment is made, whichever is later. The grant is not includible in the recipient's income for federal income tax purposes.

Certain organizations are ineligible to receive the grant, including governmental organizations, tax-exempt entities, and certain partnerships or other pass-through entities.

Additional guidance is expected to be released on or before May 21, 2010. For more information, contact Michael Solomon at (415) 875-2379 or Melinda Vance at (650) 335-7219.

©2010 Fenwick & West LLP. All Rights Reserved

This alert is intended by Fenwick & West LLP to summarize recent developments in the law. It is not intended, and should not be regarded, as legal advice. Readers who have particular questions about these issues should seek advice of counsel.

IRS Circular 230 Disclosure: To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal tax advice in this communication (including attachments) is not intended or written by Fenwick & West LLP to be used, and cannot be used, for the purpose of (i) avoiding penalties under the internal revenue code or (ii) promoting, marketing, or recommending to another party any transaction or matter addressed herein.​